Pharma BD Deal Intelligence
Galmed to Acquire Colospan for USD 4.5M. Galmed Pharmaceuticals announced a definitive agreement to acquire Colospan Ltd., combining the latter's…
Galmed To Acquire Colospan, Creating GI-Focused Platform; Stock Down. Galmed shares fell more than 16% on announcement day to $0.58, reflecting investor…
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market. The $4.5M deal ($2.5M cash + $2M shares) gives Galmed…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Galmed Pharmaceuticals agreed to acquire Israeli medical-device company Colospan for $4.5 million ($2.5 million cash + $2.0 million in Galmed ordinary shares, subject to escrow/adjustment), announced June 2026, repositioning Galmed as a GI-focused company. Colospan's CG-100 intraluminal bypass device protects the bowel anastomosis after colorectal surgery to reduce anastomotic leakage and avoid a diverting stoma; it is CE-marked under EU MDR (commercial-ready in EU/Israel) and holds FDA Breakthrough Device designation with a US pivotal trial ongoing. Galmed plans a ~$6M EU launch (Germany/Austria/Switzerland) in H2 2026. Closing expected Q2 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Galmed Pharmaceuticals Ltd. / Colospan Ltd. (this deal) | 2026 | $4M | 53 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Biogen Idec Inc. / Elan Corporation plc (Tysabri rights) | 2013 | $3.2B | 77 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
← Browse all deals · How we score deals
More: 2026 deals · Gastroenterology deals